Lausanne, Switzerland
Nagi Bioscience, founded in 2019, is at the forefront of revolutionizing the biotechnology landscape from its headquarters in Switzerland. The company's slogan, "in vivo testing at the in vitro scale," captures its mission to innovate NextGen laboratory equipment that replaces traditional animal testing with cutting-edge alternatives. Rooted in the Swiss "Health Valley," Nagi Bioscience focuses on transforming biological testing standards across pharmaceutical, cosmetic, and agro-chemical sectors.
Through its pioneering technologies leveraging small organisms like the C. elegans nematode, Nagi Bioscience offers faster, more ethical, and scalable methods for drug development and toxicology testing. This approach accelerates pipelines and introduces new standards in safety and efficacy testing, benefiting various industries.
The startup recently secured a Fr.12.40M Series A investment on 28 September 2023, led by investors including Verve Ventures, Imec.xpand, Swisscanto Invest, Excellis, and Zürcher Kantonal Bank, underscoring strong market confidence in its innovative solutions.
